CRISPR Therapeutics Reports Casgevy Revenue Surges to $76M in Q2 2026

CRISPR Therapeutics reported second-quarter 2026 Casgevy revenue of $76 million, up 78% quarter-over-quarter and 151% year-over-year, reflecting accelerating global rollout following the July 1, 2026 FDA pediatric label expansion to age 2+. The company reported net loss narrowed to $91.2 million from $208.5 million a year earlier, with cash and marketable securities of $2,364.4 million as of June 30, 2026 (bolstered by $585.4 million in net proceeds from convertible senior notes). CTX310 (targeting ANGPTL3 for severe hypertriglyceridemia and refractory hypercholesterolemia) continues in Phase 1b, with data updates expected at the European Society of Cardiology Congress and in H2 2026. The company also initiated Phase 1 trials for CTX340 (refractory hypertension) and CTX460 (alpha-1 antitrypsin deficiency).